215 related articles for article (PubMed ID: 26508513)
41. First-in-Human Trial of MIV-150 and Zinc Acetate Coformulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence, and Pharmacodynamics.
Friedland BA; Hoesley CJ; Plagianos M; Hoskin E; Zhang S; Teleshova N; Alami M; Novak L; Kleinbeck KR; Katzen LL; Zydowsky TM; Fernández-Romero JA; Creasy GW
J Acquir Immune Defic Syndr; 2016 Dec; 73(5):489-496. PubMed ID: 27437826
[TBL] [Abstract][Full Text] [Related]
42. Rectal 1% Tenofovir Gel Use Associates with Altered Epidermal Protein Expression.
Romas L; Birse K; Mayer KH; Abou M; Westmacott G; Giguere R; Febo I; Cranston RD; Carballo-Diéguez A; McGowan I; Burgener A
AIDS Res Hum Retroviruses; 2016; 32(10-11):1005-1015. PubMed ID: 27316778
[TBL] [Abstract][Full Text] [Related]
43. Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study.
Dai JY; Hendrix CW; Richardson BA; Kelly C; Marzinke M; Chirenje ZM; Marrazzo JM; Brown ER
J Infect Dis; 2016 Feb; 213(3):335-42. PubMed ID: 26123563
[TBL] [Abstract][Full Text] [Related]
44. Effects of gel volume on pharmacokinetics for vaginal and rectal applications of combination DuoGel-IQB4012, a dual chamber-dual drug HIV microbicide gel, in pigtailed macaques.
Pereira LE; Singletary T; Martin A; Dinh CT; Deyounks F; Holder A; McNicholl J; Buckheit KW; Buckheit RW; Ham A; Katz DF; Smith JM
Drug Deliv Transl Res; 2018 Oct; 8(5):1180-1190. PubMed ID: 29761350
[TBL] [Abstract][Full Text] [Related]
45. Design and in vitro evaluation of tenofovir-loaded vaginal gels for the prevention of HIV infections.
Timur SS; Şahin A; Aytekin E; Öztürk N; Polat KH; Tezel N; Gürsoy RN; Çalış S
Pharm Dev Technol; 2018 Mar; 23(3):301-310. PubMed ID: 28503983
[TBL] [Abstract][Full Text] [Related]
46. "It Was Not My Aim to Sleep There": The Impact of Timing and Location of Sex on Adherence to Coitally-Dependent HIV Pre-exposure Prophylaxis.
Scorgie F; Stadler J; Baron D; Ju S; Ikaneng T; Mabude Z; Makgopa S; Malefo MA; Manenzhe KN; Mazibuko T; Ntjana H; Nkala B; Palanee-Phillips T; Gray G; Rees H; Delany-Moretlwe S
AIDS Behav; 2018 Nov; 22(11):3692-3704. PubMed ID: 29909589
[TBL] [Abstract][Full Text] [Related]
47. Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring.
Thurman AR; Ravel J; Gajer P; Marzinke MA; Ouattara LA; Jacot T; Peet MM; Clark MR; Doncel GF
Front Cell Infect Microbiol; 2022; 12():799501. PubMed ID: 35350436
[TBL] [Abstract][Full Text] [Related]
48. Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women.
Burns RN; Hendrix CW; Chaturvedula A
J Clin Pharmacol; 2015 Jun; 55(6):629-38. PubMed ID: 25581815
[TBL] [Abstract][Full Text] [Related]
49. Pre-exposure Prophylaxis Adherence Measured by Plasma Drug Level in MTN-001: Comparison Between Vaginal Gel and Oral Tablets in Two Geographic Regions.
Minnis AM; van der Straten A; Salee P; Hendrix CW
AIDS Behav; 2016 Jul; 20(7):1541-8. PubMed ID: 25969178
[TBL] [Abstract][Full Text] [Related]
50. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
Parikh UM; Mellors JW
Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
[TBL] [Abstract][Full Text] [Related]
51. Acceptability of a Tenofovir Disoproxil Fumarate Intravaginal Ring for HIV Pre-Exposure Prophylaxis Among Sexually Active Women.
Dobkin A; McWalters J; Barnett R; Ray LL; Espinoza L; McGinn AP; Atrio JM; Keller MJ
Sex Transm Dis; 2020 Dec; 47(12):819-824. PubMed ID: 33186337
[TBL] [Abstract][Full Text] [Related]
52. Effect of Hormonal Contraception on Pharmacokinetics of Vaginal Tenofovir in Healthy Women: Increased Tenofovir Diphosphate in Injectable Depot Medroxyprogesterone Acetate Users.
Thurman AR; Schwartz JL; Brache V; Chen BA; Chandra N; Kashuba ADM; Weiner DH; Mauck C; Doncel GF
J Acquir Immune Defic Syndr; 2019 Jan; 80(1):79-88. PubMed ID: 30212395
[TBL] [Abstract][Full Text] [Related]
53. Tenofovir concentrations in hair strongly predict virologic suppression in breastfeeding women.
Murnane PM; Bacchetti P; Currier JS; Brummel S; Okochi H; Phung N; Louie A; Kuncze K; Hoffman RM; Nematadzira T; Soko DK; Owor M; Saidi F; Flynn PM; Fowler MG; Gandhi M
AIDS; 2019 Aug; 33(10):1657-1662. PubMed ID: 31021852
[TBL] [Abstract][Full Text] [Related]
54. Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel.
Gao Y; Katz DF
PLoS One; 2013; 8(9):e74404. PubMed ID: 24040241
[TBL] [Abstract][Full Text] [Related]
55. Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B).
Robinson JA; Marzinke MA; Bakshi RP; Fuchs EJ; Radebaugh CL; Aung W; Spiegel HM; Coleman JS; Rohan LC; Hendrix CW
AIDS Res Hum Retroviruses; 2017 Apr; 33(4):339-346. PubMed ID: 27809557
[TBL] [Abstract][Full Text] [Related]
56. Hypo-osmolar Formulation of Tenofovir (TFV) Enema Promotes Uptake and Metabolism of TFV in Tissues, Leading to Prevention of SHIV/SIV Infection.
Xiao P; Gumber S; Marzinke MA; Date AA; Hoang T; Hanes J; Ensign LM; Wang L; Rohan L; Fuchs EJ; Hendrix C; Villinger F
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084755
[TBL] [Abstract][Full Text] [Related]
57. Brief Report: Routine Use of Oral PrEP in a Phase 2 Rectal Microbicide Study of Tenofovir Reduced-Glycerin 1% Gel (MTN-017).
Liu AY; Norwood A; Gundacker H; Carballo-Diéguez A; Johnson S; Patterson K; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Mayer KH; Zorrilla C; Buchbinder S; Piper JM; Lama JR; Cranston RD
J Acquir Immune Defic Syndr; 2019 Aug; 81(5):516-520. PubMed ID: 31299013
[TBL] [Abstract][Full Text] [Related]
58. Preexposure Prophylaxis with Tenofovir/Emtricitabine Prevents HIV Infection In Men who Have Unprotected Anal Intercourse.
Ebell MH
Am Fam Physician; 2016 Mar; 93(6):520. PubMed ID: 26977839
[No Abstract] [Full Text] [Related]
59. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.
Keller MJ; Zerhouni-Layachi B; Cheshenko N; John M; Hogarty K; Kasowitz A; Goldberg CL; Wallenstein S; Profy AT; Klotman ME; Herold BC
J Infect Dis; 2006 Jan; 193(1):27-35. PubMed ID: 16323128
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy.
Beigi R; Noguchi L; Parsons T; Macio I; Kunjara Na Ayudhya RP; Chen J; Hendrix CW; Mâsse B; Valentine M; Piper J; Watts DH
J Infect Dis; 2011 Nov; 204(10):1527-31. PubMed ID: 21930612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
